ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Attenuation of imidacloprid deleterious effect on hepatic and neural tissues via acetylsalicylic acid: targeting HMGB1/caspase-3 axis and inflammatory pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imidacloprid (IMID), a neonicotinoid insecticide, is widely utilized but has been implicated in systemic toxicities affecting hepatic, renal, and cerebral tissues. Recent observations indicate concurrent field application of IMID with acetylsalicylic acid (ASA), producing synergistic in plant protection. This study investigates the modulatory impact of ASA on IMID-induced hepatoneurotoxicity in male albino rats. Rats (n = 20) were allocated into four experimental groups: control, ASA-treated (40 mg/kg b.w.), IMID-treated (20 mg/kg b.w.), and IMID + ASA combination. Serum biomarkers of hepatic injury such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, and total protein were estimated alongside brain acetylcholinesterase (AchE) activity. Oxidative stress parameters were assessed by measuring malondialdehyde (MDA) concentrations and antioxidant enzyme activities, specifically superoxide dismutase (SOD) and catalase (CAT), in liver and brain homogenates. Gene expression of pro-inflammatory cytokine, including high mobility group box 1 (HMGB1), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), and immunohistochemical expression of nuclear factor kappa B (NF-κB P65) were analyzed. IMID exposure resulted in significant hepatocellular and neuronal damage characterized by elevated serum ALT and AST, hypoalbuminemia, hypoproteinemia, increased MDA, suppression of SOD and CAT activities, and upregulated mRNA expression of TNF-α, IL-6, and HMGB1. Co-administration of ASA markedly mitigated these biochemical and histopathological alterations, normalizing antioxidant defenses and downregulating inflammatory mediators and NF-κB activation. The obtained results suggest that ASA is not toxic in this context and may actually protect against the liver and brain damage caused by IMID by dampening the oxidative stress and inflammatory responses driven by HMGB1 and NF-κB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.